Go Kimura
Impact in
- Pulmonary and Respiratory Medicine top 0.5%
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Prostate Cancer Diagnosis and Treatment
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Bone health and treatments
Papers in
-
- Renal cell carcinoma treatment 51
- Prostate Cancer Treatment and Research 22
- Prostate Cancer Diagnosis and Treatment 16
- Surgery 34
- Bladder and Urothelial Cancer Treatments 24
- Urinary and Genital Oncology Studies 9
- Co-authors
- Yukihiro Kondo (56 shared papers)Hirotsugu Uemura (20 shared papers)Yoko Fujita‐Yamaguchi (2 shared papers)Yoshihiko Tomita (15 shared papers)Mark H. Kawachi (2 shared papers)Masatoshi Eto (15 shared papers)Nobuo Shinohara (12 shared papers)Mototsugu Oya (9 shared papers)
- Journals
- Japanese Journal of Clinical Oncology (15 papers)International Journal of Urology (12 papers)International Journal of Clinical Oncology (10 papers)BMC Urology (6 papers)Annals of Oncology (5 papers)
- Partner nations
- JapanUnited StatesSouth Korea
In The Last Decade
Go Kimura
128 papers receiving 5.3k citations
Go Kimura's Hit Papers
Peers
Comparison fields: 5 of 90
- Pulmonary and Respiratory Medicine 3.6k
- Oncology 787
- Radiology, Nuclear Medicine and Imaging 321
- Surgery 513
- Health Informatics 24
Countries citing papers authored by Go Kimura
This map shows the geographic impact of Go Kimura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Go Kimura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Go Kimura more than expected).
Fields of papers citing papers by Go Kimura
This network shows the impact of papers produced by Go Kimura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Go Kimura. The network helps show where Go Kimura may publish in the future.
Co-authors
The 25 scholars most cited alongside Go Kimura, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 142 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Enzalutamide in Metastatic Prostate Cancer before Chemotherapy Hit paper breakdown → | 2014 | 2460 |
| 2 | Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2020 | 408 |
| 3 | Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study Hit paper breakdown → | 2016 | 343 |
| 4 | Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2019 | 313 |
| 5 | Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2022 | 212 |
| 6 | 2019 | 112 | |
| 7 | 1996 | 106 | |
| 8 | Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study Hit paper breakdown → | 2024 | 99 |
| 9 | 2016 | 70 | |
| 10 | 1998 | 56 | |
| 11 | 2011 | 54 | |
| 12 | 2017 | 54 | |
| 13 | 1996 | 44 | |
| 14 | 2019 | 42 | |
| 15 | 2019 | 41 | |
| 16 | 2016 | 40 | |
| 17 | 2007 | 38 | |
| 18 | 2004 | 37 | |
| 19 | 2016 | 36 | |
| 20 | 2013 | 29 |
About Go Kimura
Go Kimura is a scholar working on Pulmonary and Respiratory Medicine, Surgery, Oncology, Pharmacology and Cancer Research, having authored 142 papers that have together received 5.4k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (51 papers), Bladder and Urothelial Cancer Treatments (24 papers), Prostate Cancer Treatment and Research (22 papers), Prostate Cancer Diagnosis and Treatment (16 papers), Urinary and Genital Oncology Studies (9 papers), Cancer Immunotherapy and Biomarkers (8 papers), AI in cancer detection (5 papers) and Inflammatory mediators and NSAID effects (4 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (3.6k citations), Oncology (787 citations), Radiology, Nuclear Medicine and Imaging (321 citations), Surgery (513 citations) and Health Informatics (24 citations). Go Kimura has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Yukihiro Kondo, Hirotsugu Uemura, Yoko Fujita‐Yamaguchi, Yoshihiko Tomita, Mark H. Kawachi, Masatoshi Eto, Nobuo Shinohara, Mototsugu Oya, Jun Akatsuka and Satoshi Fukasawa. Their work appears in journals such as Japanese Journal of Clinical Oncology, International Journal of Urology, International Journal of Clinical Oncology, BMC Urology and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.